C5 and COVID-19: As part of the phase 3 PANAMO trial, drug concentrations for vilobelimab were analysed alongside C5a levels and the occurrence of antidrug antibodies (ADAs) to vilobelimab in invasively mechanically ventilated patients with COVID-19.